An estimated 5 percent of the world’s population is diagnosed with one of a group of heterogeneous autoimmune rheumatic diseases (ARDs) including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and Sjogren’s syndrome (SS). Not only do these diseases share mechanisms and risk factors, they are often comorbid conditions recognized as polyautoimmune (PolyA) manifestations of the same underlying dysfunction.
Polymyalgia rheumatica treatment varies significantly in glucocorticoid dosages, tapering strategies and DMARD use. EULAR and ACR have published treatment recommendations. In this slideshow, we highlight the recommendations.
EULAR has issued new treatment guidelines for antiphospholipid syndrome, a disorder of the immune system that causes blood clots. Among the recommendations, high risk individuals who carry the antiphospholipid antibody should take low-dose aspirin, even if they are asymptomatic. This also applies to systemic lupus erythematosus patients and women with a history of obstetric antiphospholipid syndrome.
Sjögren’s Syndrome affects American Indians at a higher rather rate than other ethnic groups, but the lack of classically-associated disease symptoms makes diagnosis difficult, new research shows.
Rheumatoid arthritis patients and rheumatology providers share many of the same concerns over obstacles that make it harder to reach treat-to-target goals, according to a new study.
Abnormal nail folds with a pattern indicating systemic sclerosis (SSc) is common in patients with Raynaud's syndrome, shows a study recently published in the Journal of Rheumatology. It can also be present in patients with other forms of connective tissue disease, such as primary Sjögren syndrome, systemic lupus erythematosus, rheumatoid arthritis and mixed connective tissue disease. An SSc abnormal nail growth pattern was also found to be associated with abnormal pulmonary function tests (PFT). Learn more here in this slideshow.